SciSparc (SPRC) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$679,000.00

Revenue (quarter)

$284,000.00

Revenue growth (year over year)

−38.39%

Gross profit (trailing twelve months)

$483,000.00

Gross margin

71.13%

Net income (trailing twelve months)

−$9.2M

Net income (quarter)

−$6.1M

Net income growth (year over year)

+35.71%

Net margin

−1355.38%

Return on equity

−519.89%

EPS (trailing twelve months)

$52.10

Book value per share

$6.88

P/E (trailing twelve months)

—

Price to book

0.21

Debt to assets

39.05%

Payout ratio

—

Dividend yield

—

Company profile

SciSparc Ltd is a specialty clinical stage pharmaceutical company. It is engaged in developing several immunotherapy products and it owns patents in the immunotherapy field. It is focused on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. The company has two operating reportable segments; development of drugs based on cannabinoid molecules to be approved by an official regulatory authority (the company's operation); and online sales of a various range of hemp-based products including hemp gummies, hemp oil capsules, hemp gel, hemp cream, detox pills, height pills, antibacterial creams, and anti-aging creams, among other beauty and hair treatment products that are all manufactured in the United States.

• Is SciSparc (SPRC) profitable?

  No. SciSparc reported a net loss of $9.2M over the trailing twelve months.

• How much revenue does SciSparc (SPRC) make?

  SciSparc generated $679,000.00 in revenue over the trailing twelve months, down 38.39% year over year.

• How do I buy stock in SciSparc (SPRC)?

  SPRC trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.